Genmab A/S

NasdaqGS:GMAB 株式レポート

時価総額：US$16.4b

Genmab マネジメント

マネジメント 基準チェック /34

Genmabの CEO はJan G.J. de Winkelで、 Jun2010年に任命され、 の在任期間は 15.92年です。 の年間総報酬は$ 10.70Mで、 14%給与と86%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.07%を直接所有しており、その価値は$ 176.69M 。経営陣と取締役会の平均在任期間はそれぞれ6.2年と8.2年です。

主要情報

Jan G.J. de Winkel

最高経営責任者

US$10.7m

報酬総額

CEO給与比率14.02%
CEO在任期間15.9yrs
CEOの所有権1.1%
経営陣の平均在職期間6.2yrs
取締役会の平均在任期間8.2yrs

経営陣の近況

Recent updates

Seeking Alpha • Apr 09

Genmab: Multiple Binaries Could Alter The Thesis

Summary Genmab faces a pivotal transition as DARZALEX royalties end by 2029–2032, but multiple late-stage oncology catalysts could redefine its growth trajectory. Upcoming registrational readouts for EPKINLY, Rina-S, and petosemtamab in 2026–2027 could drive multi-billion-dollar peak sales and diversify GMAB’s revenue base. GMAB trades at a discounted 4x 2026 and 2.5x 2030 forward price-to-sales, despite strong double-digit revenue and EPS growth projections post-OpEx ramp. I maintain a 4/5 conviction rating, planning selective buying below $28.25 and profit-taking at $42, with risk tied to binary clinical outcomes. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Genmab's Outlook Beyond Darzalex's Patent Cliff

Summary Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company’s robust late-stage pipeline could offset DARZALEX revenue loss with new product launches expected between 2027-2031. Genmab’s strong balance sheet with $2.9 billion in cash and no long-term debt provides financial flexibility for R&D and strategic acquisitions. The current valuation aligns with a conservative scenario where all new product launches fail suggesting limited downside risk but strong upside potential. If Phase 3 trials succeed, Genmab could see massive growth in revenue and potentially double or triple its market value, making it a low-risk, high-reward investment. Read the full article on Seeking Alpha
Seeking Alpha • Mar 14

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Summary Genmab's stock fell after J&J opted out of developing GEN3014 due to its undifferentiated efficacy and worse safety and tolerability compared to Darzalex. Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Concerns about GEN3014's safety may have impacted investors' perceptions of Genmab’s HexaBody platform. Genmab has only one early-stage HexaBody candidate in the clinic. Focus should now shift to quarterly results and upcoming clinical data updates, starting with proof-of-concept results for Rina-S in endometrial cancer and updated phase 2 results for acasunlimab. Read the full article on Seeking Alpha
Seeking Alpha • Dec 08

Genmab Is Too Attractive To Ignore

Summary Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily by Darzalex and Kesimpta. Despite some setbacks and market concerns, Genmab's long-term growth prospects remain strong, supported by growing Epkinly revenues, expanding clinical pipeline and the acquisition of ProfoundBio. Continued strong topline growth, increasing cash flows, renewed margin expansion and pipeline maturation should drive a share price recovery in 2025 and beyond. Read the full article on Seeking Alpha
Seeking Alpha • Nov 06

Genmab: Looking To Manage My Position Around Q3 Earnings

Summary Genmab's robust pipeline, strategic partnerships, and strong 2023 performance, led by DARZALEX and EPKINLY, bolster my bullish conviction despite ongoing legal disputes with Johnson & Johnson. The company's Q3 earnings on November 6th are crucial, with expectations of $817M in revenue and $0.33 EPS, potentially reversing the recent 20% share price drop. Investors should watch for updates on Genmab’s pipeline, OpEx, and DARZALEX royalty trends, as well as the impact of the ProfoundBio acquisition. Despite risks, including competition and regulatory challenges, I maintain a strong conviction in GMAB, planning to add shares if positive earnings trigger a price move above $24. Read the full article on Seeking Alpha
Seeking Alpha • Aug 23

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

Summary Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, which should boost its revenue growth rates in the following quarters. BioNTech gave up on co-development of acasunlimab, but Genmab is undeterred and expects to start a phase 3 trial by the end of the year. Operating margin pressure continues, acquisition of ProfoundBio extends the time to recovery by several quarters. Continued commercial and pipeline progress and the eventual return of margin expansion position Genmab well for long-term value creation. Read the full article on Seeking Alpha
Seeking Alpha • May 01

Genmab: A Complicated Tale

Summary Genmab's stock has lost over 35% of its value since December 2022 due to unfavorable arbitration cases and high spending on launching Epkinly. The company's top line is currently dominated by royalties from Darzalex, but it hopes Epkinly will contribute significantly to its revenue. Genmab has a strong pipeline with eight revenue-generating medications, nine clinical programs, and nine royalty candidates in Phase 2 or later trials. The company also recently made an acquisition to bolster its pipeline with some ADC candidates. A full investment analysis around Genmab A/S stock is presented in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Genmab Acquires A Missing Piece For Its Pipeline

Summary Genmab will acquire ProfoundBio for $1.8 billion in cash. The acquisition adds an important antibody drug conjugate ('ADC') platform, a missing piece in Genmab's platform. Genmab plans to advance ProfoundBio's lead candidate, Rina-S, to registrational trials with a potential approval as early as 2027. Rina-S has generated promising efficacy and safety in an early stage clinical trial in patients with ovarian and endometrial cancer. The ADC market is increasingly crowded, but an important market Genmab needs to expand into. Read the full article on Seeking Alpha
Seeking Alpha • Feb 21

Genmab: Recent Updates Support The Growth Narrative

Summary Genmab's 2023 annual report shows strong financial performance and continued clinical success, setting the company up for growth in 2024. The company's pipeline includes promising candidates and collaborations with industry giants, supporting future growth. Risks to consider include legal disputes and competition, but overall, Genmab's growth narrative remains intact. Read the full article on Seeking Alpha
Seeking Alpha • Jan 23

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Summary Genmab's appeal against Johnson & Johnson in an arbitration case has been denied, eliminating the potential upside for the company. Despite this setback, Genmab remains well positioned to create shareholder value through continued revenue growth and pipeline progression and expansion. The launch of Epkinly/Tepkinly and the growth of other products are expected to reduce Genmab's reliance on Darzalex royalties. The head-to-head phase 2 data of GEN3014 and Darzalex represent the most important clinical catalyst for Genmab this year. Read the full article on Seeking Alpha
Seeking Alpha • Jan 12

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Summary Genmab is a leading contender in the biotech industry with innovative technology, a robust pipeline, and strategic collaborations. Epcoritamab's growth is a positive trend to monitor, as it has shown impressive financial performance and secured regulatory approvals in multiple regions. DARZALEX, Genmab's flagship product, continues to be a substantial revenue driver, and investors should monitor its clinical programs for potential growth. Read the full article on Seeking Alpha
Seeking Alpha • Oct 18

Genmab reports Q3 worldwide sales of $2.05B for Darzalex

Genmab (GMAB) has announced Q3 worldwide net trade sales of $2.05B for Darzalex (daratumumab) anti-cancer monoclonal antibody medication, compared with $1.99B generated in Q2. Net trade sales were USD 1.09B in the U.S. and USD 955M in the rest of the world. Genmab (GMAB) receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to Johnson & Johnson (JNJ) subsidiary Janssen Biotech to develop, manufacture and commercialize daratumumab.
Seeking Alpha • Aug 08

Genmab improves FY 2022 guidance

Genmab (GMAB) improves FY 2022 guidance expects its 2022 revenue to be in the range of DKK 12,000M – 13,000M, an increase to the previous guidance of DKK 11,000M – 12,000M, driven primarily by the continued strong growth of DARZALEX net sales as well as the positive impact of the strong U.S. Dollar.  Such royalties are based on Genmab’s revised estimate of DARZALEX 2022 net sales of USD 7.8B – 8.2B compared to Genmab’s previous estimate of USD 7.5B – 8.0B. Anticipates its 2022 operating expenses to be in the range of DKK 7,600M – 8,200M, an increase to the previous guidance of DKK 7,200M – 7,800M, driven by increased investment related to pipeline progression and epcoritamab launch readiness activities as well as the negative impact of the strong U.S. Dollar. Operating profit to be in the range of DKK 3,800M – 5,400M, an increase to the previous guidance of DKK 3,200M – 4,800M.
Seeking Alpha • Jul 19

Genmab reports Q2 worldwide net sales of DARZALEX $1.99B

Genmab (GMAB) said global net sales of Darzalex reported by Johnson & Johnson (JNJ) rose 38.6% to $1.99B in Q2. Net trade sales were USD 1.02B in the U.S. and $965M in the rest of the world. Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous formulations, under an license agreement with J&J unit Janssen Biotech. Shares are up 2.84% premarket.
Seeking Alpha • Jun 28

Genmab: A Royalty Powerhouse With A Strong Pipeline

Genmab is receiving substantial and growing royalties from big pharma partners. The royalties are helping the company build its pipeline and to establish its own commercial infrastructure. Epcoritamab could be Genmab's next blockbuster. The stock is not cheap but increasing investments should lead to increased profits in the long run.

CEO報酬分析

Genmab の収益と比較して、Jan G.J. de Winkel の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

US$821m

Dec 31 2025US$11mUS$2m

US$963m

Sep 30 2025n/an/a

US$2b

Jun 30 2025n/an/a

US$1b

Mar 31 2025n/an/a

US$1b

Dec 31 2024US$8mUS$1m

US$1b

Sep 30 2024n/an/a

US$702m

Jun 30 2024n/an/a

US$798m

Mar 31 2024n/an/a

US$791m

Jan 01 2024n/an/a

US$631m

Sep 30 2023n/an/a

US$590m

Jun 30 2023n/an/a

US$680m

Mar 31 2023n/an/a

US$757m

Dec 31 2022US$6mUS$1m

US$785m

Sep 30 2022n/an/a

US$745m

Jun 30 2022n/an/a

US$558m

Mar 31 2022n/an/a

US$354m

Dec 31 2021US$6mUS$1m

US$452m

Sep 30 2021n/an/a

US$448m

Jun 30 2021n/an/a

US$401m

Mar 31 2021n/an/a

US$880m

Dec 31 2020US$6mUS$1m

US$781m

Sep 30 2020n/an/a

US$889m

Jun 30 2020n/an/a

US$853m

Mar 31 2020n/an/a

US$349m

Dec 31 2019US$5mUS$1m

US$325m

報酬と市場: Jan G.J.の 総報酬 ($USD 10.70M ) は、 US市場 ($USD 14.79M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jan G.J.の報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。

CEO

Jan G.J. de Winkel (64 yo)

15.9yrs
在職期間
US$10,700,000
報酬

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jan G.J. de Winkel
Co-Founder15.9yrsUS$10.70m1.07%
$ 176.7m
Anthony Pagano
Executive VP & CFO6.2yrsUS$4.70m0.017%
$ 2.8m
Rayne Waller
Executive VP & Chief Technical Operations Officer1.8yrsUS$2.70mデータなし
Gregory David Mueller
Executive VPless than a yearUS$1.80mデータなし
Christopher Cozic
Executive VP & Chief People Officer8.5yrsUS$3.40mデータなし
Martine van Vugt
Executive VP & Chief Strategy Officer12.3yrsUS$2.40mデータなし
Martin Schultz
Senior Directorno dataUS$300.00k0.0014%
$ 231.8k
Judith Klimovsky
Executive VP & Chief Development Officer9.3yrsUS$5.40m0.025%
$ 4.2m
Tahamtan Ahmadi
Executive VP5.2yrsUS$5.20m0.016%
$ 2.7m
Mijke Zachariasse
VP, Head of Antibody Research Materials & Directorno dataUS$300.00k0.0014%
$ 228.5k
Takahiro Hamatani
Senior Director of Finance Japan & Non-Independent Directorno dataUS$100.00k0.00013%
$ 21.4k
Brad Bailey
Executive VP & Chief Commercial Officer1.8yrsUS$2.10mデータなし
6.2yrs
平均在職期間
53yo
平均年齢

経験豊富な経営陣: GMABの経営陣は経験豊富で経験豊富です（平均在職期間は6.2年）。

取締役

名称ポジション在職期間報酬所有権
Martin Schultz
Senior Director4.3yrsUS$300.00k0.0014%
$ 231.8k
Mijke Zachariasse
VP, Head of Antibody Research Materials & Director7.2yrsUS$300.00k0.0014%
$ 228.5k
Takahiro Hamatani
Senior Director of Finance Japan & Non-Independent Director4.3yrsUS$100.00k0.00013%
$ 21.4k
Michael Kavanagh
Senior Director1.3yrsUS$200.00k0.00086%
$ 141.4k
Anders Pedersen
Non-Independent Director22.5yrsUS$400.00k0.013%
$ 2.1m
Elizabeth O'Farrell
Independent Director4.2yrsUS$400.00k0.0031%
$ 504.6k
Deirdre Connelly
Independent Chairman of the Board9.2yrsUS$600.00k0.011%
$ 1.8m
Rolf Hoffmann
Independent Director9.2yrsUS$400.00k0.0062%
$ 1.0m
Pernille Erenbjerg
Independent Deputy Chairman11.3yrsUS$400.00k0.0089%
$ 1.5m
Paolo Paoletti
Independent Director11.3yrsUS$300.00k0.0041%
$ 670.6k
8.2yrs
平均在職期間
59.5yo
平均年齢

経験豊富なボード: GMABの 取締役会 は 経験豊富 であると考えられます ( 8.2年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/24 09:39
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Genmab A/S 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。41

アナリスト機関
James GordonBarclays
Xue ChenBarclays
Emily FieldBarclays